Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. has recently adjusted its valuation, showcasing a P/E ratio of 11 and a high return on equity of 1371.85%. Compared to peers, its metrics indicate a favorable position in the Pharmaceuticals and Biotechnology sector, despite a year-to-date stock performance lagging behind the S&P 500.

Halozyme Therapeutics, Inc. has seen a stock price increase to $67.08, with a 10.60% return over the past year, trailing the S&P 500's 25.06%. Technical indicators show mixed signals, while the company has outperformed the S&P 500 over three and ten years, indicating resilience in a competitive market.

Halozyme Therapeutics, Inc. has experienced notable stock price fluctuations, currently at $61.63 after a decline from $63.29. The company has shown significant volatility over the past year, with a 52-week high of $82.22 and a low of $47.50, while its long-term performance has outpaced the S&P 500.

Halozyme Therapeutics, Inc. has experienced recent stock fluctuations, closing at 69.22 with a 52-week range of 47.50 to 82.22. Technical indicators present a mixed outlook, while the company has shown resilience with year-to-date returns of 2.85%, outperforming the S&P 500, though longer-term performance lags behind.

Halozyme Therapeutics, Inc. reported strong financial results for the quarter ending December 2025, achieving record net sales and operating cash flow. Despite these successes, the company faces challenges with a high debt-equity ratio and negative earnings per share, while its stock performance has been mixed compared to the S&P 500.

Halozyme Therapeutics, Inc. has recently adjusted its valuation, with its stock price at $67.03. Over the past year, it has achieved a 28.21% return, surpassing the S&P 500. The company exhibits strong financial metrics, including a P/E ratio of 14 and a remarkable return on equity of 100.64%.

Halozyme Therapeutics, Inc. has recently revised its market evaluation, with its stock priced at $66.97. The company has shown varied performance compared to the S&P 500, achieving a 13.16% return over the past year and a notable 152.72% return over five years, despite trailing the index's longer-term growth.

Halozyme Therapeutics, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company boasts a market capitalization of USD 8,872 million, impressive management efficiency, and consistent positive financial results over six quarters, reinforcing its market position.

Halozyme Therapeutics, Inc. achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. With a market capitalization of USD 8,872 million, the company has demonstrated impressive management efficiency and financial health, marked by significant growth in net profit and operating profits.